Another IGF-1R inhibitor without direct ATP-binding activity, AXL1717 (Picropodophyllin) or PPP, has shown potential therapeutic characteristics in non-small cell lung cancer patients.71 This agent showed activity in mouse models of breast cancer72 but was not tested in the breast cancer. The gene discussed is IGF1R; the disease is breast carcinoma.